Founder and CEO
Susan Nemetz is CEO and founder of The NemetzGroup and Corval. A proven leader in the life science industry, Nemetz helps transform biopharma companies from early-stage to publicly traded with her ability to see strategic opportunities and cultivate talent and empower the team to achieve them.
In 2003, Susan created The NemetzGroup, which helps companies successfully navigate the commercialization spectrum through a unique and flexible consulting model. Over the past 20 years, the company has been instrumental in guiding the evolution of more than 100 biopharma companies and the development of numerous assets, from targets to lifesaving approved medicines.
Susan founded her second company, Corval, in 2018, which is built on her deep biopharma commercialization knowledge and vision to vastly improve how emerging companies define their path to market. The company’s disruptive technology platform enables early- mid-stage biopharma companies to self-navigate the complex commercialization planning process by building a validated map, headcount, and budget plan.
Prior to establishing The NemetzGroup, Susan was Vice President of International Commercial Operations at Millennium Pharmaceuticals, Inc. She also served as Vice President of Global Commercial Strategy, leading external and internal initiatives to achieve the company's commercial vision. Susan progressed through multiple commercial leadership roles at DuPont Pharmaceuticals, culminating in her role as Executive Vice President of Cardiovascular Therapeutics and Imaging.
Susan serves as an advisor to Life Science Cares, a collective effort of the life science industry to eliminate the impact of poverty on Boston neighborhoods, and was appointed to the Board of Directors at Good Shepherd Community Care, a healthcare organization focused on hospice and palliative care.
Susan received her Bachelor of Science in Business Management from the University of Minnesota.